NAUT
Nautilus Biotechnology, Inc.NASDAQHealthcare$3.31-1.49%ClosedMarket Cap: $418.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.66
P/S
0.00
EV/EBITDA
-8.30
DCF Value
$-0.15
FCF Yield
-12.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.6%
ROA
-30.9%
ROIC
-35.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-13.8M | $-0.11 |
| FY 2025 | $0.00 | $-59.0M | $-0.47 |
| Q3 2025 | $0.00 | $-13.6M | $-0.11 |
| Q2 2025 | $0.00 | $-15.0M | $-0.12 |
Analyst Ratings
View AllGuggenheimBuy
2026-02-27Trading Activity
Insider Trades
View AllPatel Sujal Mdirector, 10 percent owner, officer: CEO, President, and Secretary
BuyWed Mar 04
Mowry Annaofficer: CFO and Treasurer
SellWed Mar 04
Mallick Paragdirector, 10 percent owner, officer: Chief Scientist
SellWed Mar 04
Patel Sujal Mdirector, 10 percent owner, officer: CEO, President, and Secretary
SellWed Mar 04
Sankar Subramanianofficer: Senior VP, Product Development
SellWed Mar 04
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.99
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.